RxDoctor Payments Data

Joseph Spano, MD

Gastroenterology · Naples, FLNPI 1417068040

Payments from drug & device makers

$591in general payments, 2019–2025

Across 22 payments — averaging $26.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$147
  • Genentech, Inc.$127
  • Mauna Kea Technologies, Inc.$115
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$62
  • Nestle Healthcare Nutrition Inc.$37
  • Novo Nordisk$28
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$591100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$591 in reported general payments places this provider in the 15th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$100,676
Medicare patients
147
Services billed
1,906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide81$94,096
EliquisApixaban43$49,843
MyrbetriqMirabegron30$27,627
JardianceEmpagliflozin29$22,314
JanuviaSitagliptin Phosphate25$21,828
LyricaPregabalin13$7,435
SynthroidLevothyroxine Sodium52$6,033
KlonopinClonazepam12$3,476
Dexlansoprazole DrDexlansoprazole16$3,271
ProgesteroneProgesterone, Micronized49$2,141
Metoprolol Succinate102$1,706
Losartan Potassium121$1,434
Rosuvastatin Calcium71$1,422
Esomeprazole Magnesium24$1,307
Escitalopram Oxalate74$1,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$18$21,82825 claims
AbbVieSynthroid$147$6,03352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →